Taiwan biotech startups held over 100 business meetings at BIO 2026, showcasing their strengths in digital health and AI healthcare.

Introduction

In June 2026, the world's largest biotechnology partnering conference—the BIO International Convention—was held in San Diego. Six biomedical startups led by Startup Island TAIWAN, an entrepreneurship brand under Taiwan's National Development Council, completed over 100 one-on-one business meetings during the four-day conference, engaging intensively with global pharmaceutical companies, investment institutions, contract research organizations (CROs), and R&D partners. This number not only confirms Taiwan's dynamism in digital health, AI healthcare, and biotechnology innovation, but also reflects that the Asian biotech sector is accelerating its integration into the global medtech industry chain.

Industry Context

In recent years, the global medtech industry has been undergoing a wave of transformation from traditional pharmaceuticals to digital and precision approaches. M&A and collaborations in fields such as Digital Health, AI Healthcare, and Medical Devices have become increasingly frequent. As a bellwether for the industry, the BIO conference attracts thousands of companies and investors each year. Taiwan, as a stronghold of semiconductor and electronics manufacturing, is extending its technological advantages into the medical field, particularly forming a unique competitive edge in AI-assisted diagnostics, organoid automation platforms, and precision antibody engineering. According to Startup Island TAIWAN's plan, Taiwan aims to become a biotech innovation hub in the Asia-Pacific region by 2030, and the outcomes of BIO 2026 are undoubtedly an important milestone for this strategy.

Key Developments

The six companies in this delegation covered key segments of the medtech industry chain:

• AB DigiHealth (Digital Health) focuses on AI-assisted reproductive health solutions. Its icONE platform integrates genomics and clinical data to help IVF clinics improve embryo screening efficiency.- AB DigiHealth (Digital Health) focuses on AI-assisted reproductive health solutions. Its icONE platform integrates genomics and clinical data to help IVF clinics improve embryo screening efficiency.
• AcadeMab Biomedical (Biotechnology) focuses on cancer stem cell-targeted therapies, and its mRNA-LNP vaccine technology platform has attracted international attention.
• PlasmonicTron (Medical Devices/Automation) provides AI-based organoid manufacturing infrastructure, achieving standardization and scalability of organoid production.
• Taiwan Universe BioMedicine (Vaccine Development) is dedicated to next-generation vaccines for enterovirus and influenza, emphasizing lower costs and broader protection spectrum.
• CancerFree Biotech (Precision Medicine)'s Ex Vivo Avatar (EVA) platform uses patient blood samples to generate tumor organoids, combined with an AI system to accelerate drug screening.
• Precisemab Biotech (Antibody Engineering)'s Universal Antibody Lock™ platform can selectively activate antibodies in the tumor microenvironment, improving efficacy and safety.Despite the optimistic outlook, Taiwan’s biotech companies still face several challenges: First, most companies are in their early stages, with clinical validation and data accumulation insufficient to support large-scale commercialization. Second, international competition is fierce, with South Korea, Singapore, and Israel also actively positioning themselves in similar fields. In addition, the global medical regulatory environment is tightening, especially the increasingly complex approval requirements for AI medical devices and digital health products, which may slow down product launches. Finally, geopolitical factors may also affect cooperation between Taiwanese companies and mainland or global supply chains.